// App-Quantinova.ai

524 : The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC).

Researchers

Presenter

  • Elisa Agostinetto

Principal Investigators

  • Samuel Martel

  • Philippe Georges Aftimos

  • Noam Ponde

  • Christian Maurer

  • Sarra El-Abed

  • Yingbo Wang

  • Maria Lourdes Vicente

  • Saranya Chumsri

  • Judith Bliss

  • Judith R. Kroep

  • Marco Colleoni

  • Fausto Petrelli

  • Lucia Del Mastro

  • Alvaro Moreno-Aspitia

  • Martine J. Piccart-Gebhart

  • Marianne Paesmans

  • Evandro de Azambuja

  • Matteo Lambertini

Medical Centers

  • Institut Jules Bordet, Universite libre de Bruxelles, Brussels, Belgium

  • Data Centre, Institut Jules Bordet - Universite Libre de Bruxelles (ULB), Brussels, Belgium

  • CISSS Montérégie-Centre/Hôpital Charles-Le Moyne, Université de Sherbrooke, Greenfield Park, QC, Canada

  • Institut Jules Bordet, Universite libre de Bruxelles, Brussels, Belgium

  • A.C. Camargo Cancer Center, Sao Paulo, Brazil

  • University Hospital Cologne, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf; Cologne, Cologne, Germany

  • Breast International Group, Brussels, Belgium

  • Novartis AG, Basel, Switzerland

  • Institute Jules Bordet, Brussels, Belgium

  • Mayo Clinic, Jacksonville, FL, The Institute of Cancer Research, Clinical Trials & Statistics Unit, London, United Kingdom

  • Leiden University Medical Centre, Leiden, Netherlands

  • European Institute of Oncology, Milan, Italy

  • Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy

  • IRCCS Policlinico San Martino, Genova, Italy

  • Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genoa, Genoa, Italy

Locations

  • Belgium

  • Canada

  • Brazil

  • Germany

  • Switzerland

  • United Kingdom

  • Netherlands

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab

  • Lapatinib

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved